CLAIMS

1. An immunogenic composition comprising capsular polysaccharide of at least 25 different *S. pneumoniae* serotypes conjugated to a carrier protein, NaCl, optionally a second salt, a surfactant and an adjuvant.

2. The immunogenic composition of **claim 1**, wherein said second salt is sodium phosphate, the concentration of which ranges from about 1 mM to 50 mM, or from about 10 mM to 30 mM, or from about 15 mM to 25 mM, or from about 20 mM to 50 mM, or from about 30 mM to 50 mM, or from about 35 mM to 45 mM, or is about 20 mM, or is about 40 mM.

3. The immunogenic composition of any one of **claims 1 or 2**, wherein the concentration of NaCl ranges from about 1 mM to 300 mM, or from about 50 mM to 300 mM, or from about 100mM to 300 mM, or from about 100 mM to 200 mM, or from about 150 mM to 250 mM, or from about 200 mM to 300 mM, or is about 150 mM, or is about 245 mM.

4. The immunogenic composition of **claim 1**, further comprising succinate, the concentration of which ranges from about 1 mM to 50 mM, or from about 1 mM to 30 mM, or from 1 mM to 10 mM, or from about 5 mM to 9 mM, or is about 5 mM.

5. The immunogenic composition of any one of **claims 1 or 4**, wherein the concentration of NaCl ranges from about 1 mM to 300 mM, or from about 50 mM to 300 mM, or from about 100 mM to 250 mM, or from about 100 mM to 200 mM, or from about 100mM to 300 mM, or from about 150 mM to 250 mM, or from about 200 mM to 300 mM, or is about 245 mM, or is about 150 mM.

6. The immunogenic composition of any one of **claims 1, 4 or 5**, wherein said second salt is sodium phosphate, the concentration of which ranges from about 1 mM to 50 mM, or from about 10 mM to 30 mM, or from about 20 mM to 50 mM, or from about 15 mM to 25 mM, or

from about 30 mM to 50 mM, or from about 35 mM to 45 mM, or is about 20 mM, or is about 40 mM.

7. The immunogenic composition of any one of **claims 1, 4 or 5**, wherein said second salt is CaCl2, the concentration of which ranges from about 1 mM to 50 mM, or from about 10 mM to 30 mM, or from about 15 mM to 25 mM, or from about 20 mM to 30 mM, or is about 20 mM.

8. The immunogenic composition of any one of **claims 1, 4 or 5**, wherein said second salt is MgCl2, the concentration of which ranges from about about 1 mM to 50 mM, or from about 10 mM to 30 mM, or from about 10 mM to 50 mM, or from about 15 mM to 25 mM, or from about 30 mM to 50 mM, or from about 20 mM to 50 mM, or from about 35 mM to 45 mM, or is about 20 mM, or is about 40 mM.

9. The immunogenic composition of **claim 1**, further comprising histidine, the concentration of which ranges from about 1 mM to 50 mM, or from about 1 mM to 30 mM, or from about 10 mM to 30 mM, or from about 20 mM to 30 mM, or is about 30 mM.

10. The immunogenic composition of any one of **claims 1 or 9**, wherein the concentration of NaCl ranges from about 1 mM to 300 mM, or from about 50 mM to 300 mM, or from about 100mM to 300 mM, or from about 100 mM to 200 mM, or from about 150 mM to 250 mM, or from about 200 mM to 300 mM, or is about 150 mM, or is about 245 mM.

11. The immunogenic composition of any one of **claims 1, 9 or 10**, further comprising sodium phosphate, wherein the concentration of sodium phosphate ranges from about 1 mM to 50 mM, or from about 10 mM to 30 mM, or from about 15 mM to 25 mM, or from about 20 mM to 50 mM, or from about 30 mM to 50 mM, or from about 35 mM to 45 mM, or is about 20 mM, or is about 40 mM.

12. The immunogenic composition of any one of **claims 1 to 11**, wherein the pH of said composition ranges from about pH 5.0 to pH 7.5, or from about pH 5.5 to pH 7.5, or from about pH 5.5 to pH 6.0, or from about pH 5.6 to pH 7.0, or from about pH 5.8 to pH 6.0, or is about pH 5.8.

13. The immunogenic composition of any one of **claims 1 to 12**, wherein said surfactant is a polysorbate, optionally polysorbate 20 or polysorbate 80.

14. The immunogenic composition of **claim 13**, wherein the concentration of said surfactant ranges from about 0.001% to 1%.

15. The immunogenic composition of any one of **claims 1 to 14**, wherein the concentration of each serotype capsular polysaccharide in a dose of said composition ranges from about about 1.5 μg to about 5.0 μg, or is about 2.2 μg or is about 4.4 μg.

16. The immunogenic composition of **claim 15**, wherein the volume of a dose of said composition is about 0.5 mL.

17. The immunogenic composition of any one of **claims 1 to 16**, wherein said adjuvant is an aluminum salt, optionally an aluminum salt, optionally aluminum phosphate.

18. The immunogenic composition of **claim 17**, wherein said adjuvant is aluminum phosphate, the concentration of which ranges from about about 0.1 mg/mL to about 1.0 mg/mL.

19. The immunogenic composition of **claim 17**, wherein said adjuvant is aluminum phosphate, which forms a sediment in equilibrium with the liquid phase of said composition after about 2 hours to 5 hours of settling time.

20. The immunogenic composition of any one of **claims 1 to 19**, wherein after storage in a prefilled syringe for about 1 month at a temperature of about 2 °C to 8 °C, said composition can be resuspended with about 1 to 10 handshakes.

21. The immunogenic composition of any one of **claims 1 to 20**, wherein the sedimentation velocity of said composition is faster than a control composition comprising capsular polysaccharide of *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, each individually conjugated to CRM_{197}, 5 mM Succinate (pH 5.8), 150 mM NaCl, 0.02% polysorbate 80, and 0.25 mg/mL aluminum as aluminum phosphate.

22. The immunogenic composition of any one of **claims 1 to 21**, wherein said composition comprises capsular polysaccharide from at least one *S. pneumoniae* serotype selected from the group consisting of serotypes 15A, 23A, 23B, 24F, and 35B.

23. A prefilled syringe comprising the immunogenic composition of any one of **claims 1 to 22**.